Articles tagged "Graft arterlosclerosis"

2022 American Transplant Congress
Bcl6b is a Putative Regulator of Endothelial Identity and Endmt
N. M. Valenzuela
Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
*Purpose: Loss of endothelial cell (EC) identity is central to endothelial to mesenchymal transition (EndMT) implicated in neointimal hyperplasia in transplant vasculopathy. However, the molecular…
2022 American Transplant Congress
A Sustained Injury Response by Regulatory T Cells (Treg) Contributes to Fibrosis to Promote Chronic Rejection After Heart Transplantation
J. Bou Saba¹, L. Fan¹, X. Zhang¹, T. Li¹, L. R. Mathews¹, G. Dwyer², E. Colon², M. J. Calderon³, K. E. Helfrich³, M. A. Ross³, S. C. Watkins³, H. Turnquist¹
¹Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²Immunology, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ³Cell Biology, University of Pittsburgh, Center for Biologic Imaging, Pittsburgh, PA
*Purpose: Chronic rejection (CR) results from the development of immunosuppressant-resistant allograft vasculopathy and fibrosis and remains a leading cause of recipient death one-year post-heart transplant…
2022 American Transplant Congress
Improvement in Kidney Function After Early Conversion to Belatacept-Based Regimen in Allografts with Biopsy-Proven Donor Vascular Disease
T. Ommert¹, J. Javier¹, J. Jackson¹, C. Klein²
¹Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA, ²Piedmont Transplant Institute, Atlanta, GA
*Purpose: Donor arteriosclerosis in the kidney allograft predicts poorer graft outcomes and is a risk factor for tacrolimus-induced nephrotoxicity. Belatacept conversion has been utilized as…
2022 American Transplant Congress
Targeting the Bet Family Protein Brd4 Inhibits Inflammatory Macrophages and Promotes Heart Allograft Tolerance
X. Xiao
Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: Infiltration of allografts by inflammatory macrophages is frequently associated with chronic graft loss In both animal models and clinical settings, but the mechanisms that…
2021 American Transplant Congress
Findings from the Bareto Study: Associations Between Chronic Vascular Changes and 10-year Transplant Graft Outcomes
L. Kamal¹, D. Stewart², J. Foutz², H. McGehee², P. Saravanane¹, S. Yu¹, R. Yusfi¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²UNOS, Richmond, VA
*Purpose: As part of a broader study on Biopsy, Anatomy, and Resistance Effects on Transplant Outcomes (BARETO), we aim to characterize the poorly understood relationship…
2020 American Transplant Congress
Age-Enhanced Transplant Vasculopathy Associates with Impaired Vascular Mitophagy
M. Blin¹, D. Tyrrell¹, S. Wood¹, D. Farris¹, S. G. Tullius², D. R. Goldstein¹
¹Micro and Immunology/Internal Medicine, University of Michigan, Ann Arbor, MI, ²Transplant Surgery, Brigham and Women's Hospital, Boston, MA
*Purpose: Donor aging leads to increased chronic allograft vasculopathy (CAV) for unclear reasons. Here, we investigated whether impaired alterations in mitophagy, a mechanism to remove…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2020 American Transplant Congress
Taking it to the Max: Extremely Low LDL May Provide Benefit for Prevention of Cardiac Allograft Vasculopathy
R. Lee¹, E. J. Henricksen¹, Y. Moayedi², K. Y. Feng³, J. Han³, W. Yang⁴, R. Imai¹, J. J. Teuteberg⁴, K. K. Khush⁴
¹Pharmacy, Stanford Health Care, Stanford, CA, ²University Health Network, Toronto, ON, Canada, ³Medicine, Stanford University, Stanford, CA, ⁴Cardiac Transplant, Stanford University, Stanford, CA
*Purpose: Routine use of statins is the only Class I ISHLT recommendation in heart transplantation (HT) to reduce cardiac allograft vasculopathy (CAV) and improve survival.…
2020 American Transplant Congress
Regulatory T Cell-Derived Amphiregulin Activates Fibroblasts to Promote Chronic Rejection after Heart Transplantation
L. Fan¹, X. Zhang¹, T. Li¹, L. R. Mathews¹, G. K. Dwyer², M. J. Calderon³, K. E. Helfrich³, M. A. Ross³, S. C. Watkins³, H. R. Turnquist¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Immunology, University of Pittsburgh, Pittsburgh, PA, ³Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, PA
*Purpose: Chronic rejection (CR) after organ transplantation (Tx) manifests as function-limiting allograft fibrosis and vasculopathy. Current immunosuppressants fail to prevent CR and insights into the…